Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-25-055078
Filing Date
2025-06-02
Accepted
2025-05-30 21:43:30
Documents
17
Period of Report
2025-04-30
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm2516317d1_8ka.htm   iXBRL 8-K/A 211111
2 EXHIBIT 99.5 tm2516317d1_ex99-5.htm EX-99.5 222300
3 EXHIBIT 99.6 tm2516317d1_ex99-6.htm EX-99.6 141071
4 EXHIBIT 99.7 tm2516317d1_ex99-7.htm EX-99.7 352072
5 EXHIBIT 99.8 tm2516317d1_ex99-8.htm EX-99.8 56732
  Complete submission text file 0001104659-25-055078.txt   1365977

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA limn-20250430.xsd EX-101.SCH 3359
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE limn-20250430_def.xml EX-101.DEF 28661
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE limn-20250430_lab.xml EX-101.LAB 38284
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE limn-20250430_pre.xml EX-101.PRE 26870
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2516317d1_8ka_htm.xml XML 7021
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Filer) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-42626 | Film No.: 251012926
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)